Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study.

Luis G Paz-Ares Stephane Champiat W Victoria Lai Hiroki Izumi Ramaswamy Govindan Michael J BoyerHorst-Dieter HummelHossein Borghaei Melissa Lynne Johnson Neeltje SteeghsFiona BlackhallAfshin Dowlati Noemí Reguart Tatsuya Yoshida Kai He Shirish M Gadgeel Enriqueta Felip Font Yiran ZhangAmrita PatiMukul MinochaSujoy MukherjeeAmanda GoldrickDirk NagorsenNooshin Hashemi Sadraei Taofeek Kunle Owonikoko

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

In patients with heavily pretreated SCLC, tarlatamab demonstrated manageable safety with encouraging response durability. Further evaluation of this promising molecule is ongoing.

Keyphrases

small cell lung cancer
open label
cancer therapy
brain metastases
clinical trial
drug delivery